Wiseheart Medval
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Wiseheart Medval - overview
Established
2021
Location
Beijing, Beijing, China
Primary Industry
Biotechnology
About
Based in Beijing, China and founded in 2021, Beijing Huixin Wiseheart Medval Biotechnology Co. , Ltd, trading under the name Wiseheart Medval, operates as a biopharmaceutical company, focusing on cell therapy for neurological diseases. The company built a GMP-grade cell product manufacturing plant in Beijing's Zhongguancun Life Science Park. It has cooperated with Xuanwu Hospital.
In January 2026, Wiseheart Medval raised over CNY 100 million in series A funding from new lead investor Beijing Jingneng Tongxin Investment Management, returning investor BCT Capital and new investor Fuzhi Investment. The company uses reprogramming technology and non-integrating systems to obtain neural stem cells (iNSC) directly induced from human peripheral blood single nucleated cells or fibroblasts, and simultaneously and directionally differentiate them into dopaminergic neural precursor cells (iNSC-DAP). Its core products, Dopaminergic Neural Precursor Cells (iNSC-DAP) Injection, can treat Parkinson's disease with clinical intervention through stereotactic transplantation clinical technology. This technology allows for autologous or allogeneic cell therapy, avoiding the ethical issues involved in embryonic stem cell harvesting.
The company’s revenue is generated by the research, development, and commercialization of cell therapy drugs and regenerative medicine technologies. The company plans to use the series A funding to advance the clinical research of cell therapy products for nervous system diseases and accelerate the transformation of innovative results into clinical and industrial applications.
Current Investors
Green Pine Capital Partners, Jiuzhi Capital, BCT Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare IT
Website
www.wiseheartmed.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Wiseheart Medval - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Wiseheart Medval | - | ||||||||
| Unspecified Round | Completed | Wiseheart Medval | - | ||||||||
| Angel | Completed | Wiseheart Medval | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.